Owasso, OK, March 28, 2018 --(PR.com
)-- GnuPharma, an early stage research, development, and manufacturing company is announcing its continued developed of its landmark pending patent. The company’s patent claims the ability to influence the endocannabinoid system (the system affected by cannabis) with non-cannabis plants. The company is well on its way to validating scientifically that some of the medicinal properties of cannabis can be realized using non-cannabis plants and without the psychoactive effects associated with THC use. Further, this can be accomplished with herbs that are already classified as generally regarded as safe (GRAS) by the FDA.
GnuPharma’s President Chip Paul remarked, “We are seeing outstanding anecdotal evidence with some of our products. Frankly what we are seeing has exceeded even our early expectations. When we began seeing the results, we knew that it was critical to have these observations replicated by the scientific community.” In the Spring of 2017, the company began working toward validating its findings through a collaboration with a major university. “Adding additional scientific studies will distinguish GnuPharma’s products and will truly benefit its customers,” said Dr. David Colby, GnuPharma’s Science Advisor.
GnuPharma would prefer to license its technology but has productized the concept of what it can do. “We are building an entrepreneurial platform, and we want to foster a symbiotic relationship between licensees, white label partners, and distribution points,” said Cynthia Paul, Senior Vice-President of Marketing. Peak10Health, a large Amazon distributor, recently added GnuPharma products to their offerings. “We are excited about working with a company like GnuPharma. Their work is on the cutting edge, and we look forward to helping bring their products into the spotlight!” said Kevin Balster, co-owner of Peak10 Health.
Josh Unger, Manager at Raw Health Products, is using GnuPharma’s tincture based products to enhance a product offering they are developing. “The GnuPharma tincture line allows us an additive which can be purposed around our new water based products.”
EndoPets, an innovative sales and marketing company, asked GnuPharma to develop a pet line which it will soon introduce on the West coast. “The endocannabinoid system is shared by almost all life on the planet, all animals could benefit! We were excited by GnuPharma’s technology that can help us create wonderful new products for pets,” said EndoPets CEO Jim Turner.
As to product effectiveness, Ashlee Byrd, a veteran, who has suffered with mobility commented, “The GnuPharma Relief and Foundation products have allowed me to transition from some pretty heavy medication I was taking for my injuries. The GnuPharma products are great for me and I want to tell everyone about them!”
More information about opportunities with GnuPharma Corp can be found on the companies website at www.gnupharma.com